Address
Novartis Venture Funds
Novartis International AG WSJ-200.220 P.O. Box
4002 Basel
Switzerland
Phone
Industry
Recent investment activity
KANDO id: 30987
Company type
The corporate venturing arm of Novartis.Funding rounds
Investment activity status
Active investor
Selected investments
Displaying 1 - 25 of 49| Company | Profile | Country | Date Sort ascending | Funding | ||
|---|---|---|---|---|---|---|
![[current-page:title] logo](/sites/default/files/styles/icon/public/default_images/_no-logo.png?itok=AH4pbDYM){kind=icon}
|
Tokai Pharmaceuticals Inc | Developer of prostate cancer drugs | Series E | |||
|
|
Opsona Therapeutics Ltd | Innate immune drug development company | Series C | |||
|
|
Aerpio Therapeutics Inc | Series A | ||||
|
|
BioRelix Inc | Advanced fight against drug resistant microbes by attacking novel targets with novel drugs. | N/A Follow-on investment | |||
|
|
Pulmatrix Inc | Discovering a new class of host-targeted therapies that pathogen independently treat | Series B | |||
|
|
Akebia Therapeutics Inc | Series B | ||||
|
|
Cylene Pharmaceuticals Inc | Clinical stage private company developing small molecule drugs against newly validated cancer targets. | Series D | |||
|
|
Anchor Therapeutics Inc | Series B | ||||
|
|
FoldRx Pharmaceuticals Inc | N/A | ||||
|
|
Microchips Inc | Developer and tester of implanted devices for people with chronic conditions. | N/A | |||
|
|
Akebia Therapeutics Inc | Series A | ||||
|
|
PharmAbcine Inc | Develops fully human therapeutic monoclonal antibody (mAb) | Series A | |||
|
|
Intellikine | Series B | ||||
|
|
Visiogen Inc | A medical device company focused on dual-optic accommodating intraocular lens, called Synchrony, for the treatment of age-related vision loss. | Series D Initial investment | |||
|
|
Heptares Therapeutics Ltd | Series A | ||||
|
|
Intradigm Corp | Series B | ||||
|
|
Catalyst Biosciences Inc | Developer of catalytic biopharmaceutical products based on engineered human proteases. | Series C | |||
|
|
ESBATech AG | Switzerland based Biomedical Research Unit of Alcon | Series B Initial investment | |||
|
|
Ascent Therapeutics Inc | Series A | ||||
|
|
BioRelix Inc | Advanced fight against drug resistant microbes by attacking novel targets with novel drugs. | Series A Follow-on investment | |||
|
|
Cequent Pharmaceuticals | Series A | ||||
|
|
Cylene Pharmaceuticals Inc | Clinical stage private company developing small molecule drugs against newly validated cancer targets. | Series C | |||
|
|
Intradigm Corp | Series A | ||||
|
|
Biofisica Inc | Wound care company. | Series A | |||
|
|
ESBATech AG | Switzerland based Biomedical Research Unit of Alcon | Series B Initial investment |
Team
| Employee | Position | |||
|---|---|---|---|---|
| Florent Gros | [email protected] | |||
| Rudolf Gygax | [email protected] |